It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Viral capsids can adopt various geometries, most iconically characterized by icosahedral or helical symmetries. Importantly, precise control over the size and shape of virus capsids would have advantages in the development of new vaccines and delivery systems. However, current tools to direct the assembly process in a programmable manner are exceedingly elusive. Here we introduce a modular approach by demonstrating DNA-origami-directed polymorphism of single-protein subunit capsids. We achieve control over the capsid shape, size and topology by employing user-defined DNA origami nanostructures as binding and assembly platforms, which are efficiently encapsulated within the capsid. Furthermore, the obtained viral capsid coatings can shield the encapsulated DNA origami from degradation. Our approach is, moreover, not limited to a single type of capsomers and can also be applied to RNA–DNA origami structures to pave way for next-generation cargo protection and targeting strategies.
DNA and RNA origami nanostructures direct the size, shape and topology of different virus capsids in a user-defined manner while shielding encapsulated origamis from degradation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Aalto University, Department of Bioproducts and Biosystems, Aalto, Finland (GRID:grid.5373.2) (ISNI:0000 0001 0838 9418)
2 University of Helsinki, Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
3 Griffith University, Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Nathan, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
4 Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland (GRID:grid.502801.e) (ISNI:0000 0001 2314 6254)
5 University of Twente, Department of Molecules and Materials, MESA+ Institute for Nanotechnology, Enschede, Netherlands (GRID:grid.6214.1) (ISNI:0000 0004 0399 8953)
6 Aalto University, Department of Bioproducts and Biosystems, Aalto, Finland (GRID:grid.5373.2) (ISNI:0000 0001 0838 9418); Aalto University, LIBER Center of Excellence, Aalto, Finland (GRID:grid.5373.2) (ISNI:0000 0001 0838 9418); University of Tartu, Institute of Technology, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
7 Aalto University, Department of Bioproducts and Biosystems, Aalto, Finland (GRID:grid.5373.2) (ISNI:0000 0001 0838 9418); Aalto University, LIBER Center of Excellence, Aalto, Finland (GRID:grid.5373.2) (ISNI:0000 0001 0838 9418)